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Abstract
As the leading cause of cancer-related mortality, lung cancer is a worldwide health issue that is overwhelmingly caused
by smoking. However, a substantial minority (~25%) of patients with non–small cell lung cancer (NSCLC) has never
smoked. In these patients, activating mutations of the epidermal growth factor receptor (EGFR) are more likely, which
render their tumors susceptible for a finite period to treatment with EGFR tyrosine kinase inhibitors (TKIs) and confer a
better prognosis than EGFR wild-type NSCLC. On progression, due to the inevitable insurgence of resistance, TKIs are
generally followed by second- or third-line salvage chemotherapy until treatment failure, after which no standard
treatment options are available, resulting in a poor prognosis and a high risk of death. With the focus of clinical attention
on treatment with TKIs, few studies on optimal salvage therapies, including cytotoxic chemotherapy, after failure of
EGFR TKIs have been reported. Despite a paucity of available data, the aim of this review is to summarize the “no-man's
land” of TKI-failed EGFR-mutated NSCLC and expand on alternative strategies as well as potential future directions.
Neoplasia (2018) 20, 92–98

Introduction
According to the GLOBOCAN 2012 database, the most recent year for
which statistics are available, lung cancer is the most common cancer (1.8
million cases) and the leading cause of cancer-related death (1.59 million
deaths) worldwide [1]. Tobacco smoking remains the dominant cause of
all non–small cell lung cancers (NSCLCs) except in the case of
adenocarcinomas with fusions or mutations of the kinase genes such as
epidermal growth factor receptor (EGFR), which occur specifically in
light or never-smokers [2]. These mutations, which have been identified
in exons 18 to 21 of the TK domain and appear most commonly in exon
19 (del19) and in exon 21 (L858R), activate the receptor tyrosine kinase
pathway (hence the term “activating mutations”), leading to overstimulation of downstream signaling prosurvival pathways including
Ras-Raf-MAP-kinase and PI3K-Akt-mTOR that confer oncogenicity.
Activating EGFR mutations, to which tumors are “addicted” for survival,

are primarily associated with adenocarcinoma histology; frequently
mutually exclusive with other activating tumor mutations; and only
rarely found in large cell carcinomas, small cell carcinomas, and
squamous carcinomas [3]. While deletions in exon 19 and L8585R point
mutation in exon 21 are considered activating, other EGFR mutations
such as exon 20 insertions are not activating and, therefore, do not tend
to respond to EGFR tyrosine kinase inhibitor (TKI) treatment.
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The frequency of EGFR driver mutations in lung adenocarcinomas
differs according to ethnicity and sex, appearing at a rate of
approximately 10% to 15% in North Americans and Europeans [4]
and as high as 30% to 50% in East Asians [5], most commonly in
East Asian women that have never smoked. Unlike SCLC, which is
strongly linked to smoking behavior, a history of never or minimal
smoking is the strongest predictor of harboring the EGFR mutation
in NSCLC, which strongly suggests that EGFR mutagenesis arises
from nontobacco carcinogens: in fact, the total number of pack-years
smoked has been found in multiple studies to inversely correlate with
the rate of EGFR TK mutations [6,7]. In addition, the high mutation
burden typically induced by carcinogens in cigarette smoke, which
putatively leads to a higher quantity of neoantigens [8], may underlie
the generally poorer response to PD-1 inhibition in EGFR + NSCLC.
According to the Surveillance, Epidemiology, and End Results
database of the National Institutes of Health [9], lung cancer accounts
for approximately 6.4% of all malignancies, and since ~10% to 15%
of these are EGFR mutated, the lifetime prevalence of EGFR-mutated tumors is between 88,300 and 132,400, making it an orphan
disease in the United States from a prevalence count perspective
(b200,000 prevalent cases).
EGFR, a transmembrane glycoprotein, is part of the ErbB/HER
family of receptor tyrosine kinases, which includes three other
members: HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4) [10].
The presence of activating EGFR mutations in advanced NSCLC
confers sensitivity to standard-of-care TKIs such as afatinib, gefitinib,
erlotinib [11], dacomitinib, and osimertinib and predicts a better
prognosis as compared to EGFR wild-type NSCLC. While the use of
TKIs, which are superior to chemotherapy, has resulted in substantial
benefits including an initial response rate of approximately 70% and
an overall survival from 1 to nearly 3 years [12], the universality of
treatment resistance limits the duration of their use.
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Clinical management of TKI-failed patients constitutes an
uncertain “no man's land” since, to date, there are no clear guidelines,
and new accepted strategies to improve outcomes are lacking [13,14].
A retrospective analysis of 521 EGFR TKI-failed patients by Song et
al. [15] highlights the poor prognosis in this population since of the
223 patients who previously received long-term TKI therapy (N6
months), overall survival was a dismal 5 months. In the absence of
satisfactory therapeutic options and treatment guidelines after failure
of subsequent salvage second- and third-line chemotherapy EGFRpositive NSCLC is an area of high unmet medical need. A systematic
review of the available literature highlights a wealth of data from
high-quality clinical trials on clinical outcomes with TKIs and a
corresponding paucity of information and evidence pertaining to
treatment of tumors that have exhausted TKI options. With the focus
of attention on treatment with TKIs, a hotspot of clinical research,
the question of how to manage patients that exhaust TKI and
chemotherapy options is an open one. Despite the relative paucity of
available data on this subject, this review aims to summarize current
and alternative treatment strategies as well as potential future
directions in advanced TKI-failed EGFR-mutated NSCLC.
Current treatment strategies

First-line TKIs
Several randomized trials including EURTAC [16] and
OPTIMAL [17] for erlotinib; NEJGSG_ 002 [18], WJTOG 3405
[19], and IPASS [20] for gefitinib; and LUX LUNG 3 [21] and LUX
LUNG 6 [22] for afatinib have demonstrated the superiority of
EGFR TKIs to chemotherapy in terms of overall response rates and
progression-free survival (PFS) for first-line therapy (see Figure 1).
Erlotinib and gefitinib are first-generation reversible TKIs, while
afatinib and lapatinib are second-generation irreversible pan-HER

Figure 1. Patterns of clinical relapse and algorithm for EGFR mutation–positive NSCLC. Abbreviations: WBRT, whole brain radiotherapy;
M+, mutation positive.
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Figure 2. Mechanism of different EGFR TKIs. Abbreviations: HER-2, human epidermal growth factor receptor 2.

TKIs [23] that are reported to be superior to gefitinib in EGFR exon
19 deleted tumors and other less common mutations (see Figure 2).
Despite strikingly high initial response rates with these TKIs, the
development after 11 to 14 months of acquired resistance, as defined
by the Jackman criteria [24] (disease progression after objective
response or durable stable disease for N6 months on a TKI), is a
virtual fait accompli [25]. In over 60% of patients that have
progressed on first- and second-generation TKIs, the mechanism of
resistance is an acquired threonine-to-methionine amino acid
substitution at the gatekeeper position 790 of EGFR in exon 20 or
T790M [26], which increases the affinity of the EGFR kinase domain
for ATP and thereby outcompetes the binding of EGFR TKIs; the
T790M-resistant tumor cells may arise from the selective pressure of a
TKI or present de novo. Based on data from the Phase II AURA 2 trial
and the AURA extension cohort, T790M-positive tumors are
responsive to treatment with the third-generation TKI osimertinib
[27]. However, secondary mutations have also been described as a
mechanism of acquired resistance to osimertinib. In addition to
T790M, the occurrence of other resistance mechanisms including
activation of the MET pathway, HER2 amplification, mutations in
Pi3kinase and BRAF, and transformation to small cell lung cancer
supports rebiopsy at clinical progression to determine the molecular/
morphologic changes and to personalize the therapy accordingly.

Chemotherapy
After progression on osimertinib, despite a lack of strong supporting
evidence (no prospective trials comparing the efficacy of chemotherapy
regimens have been conducted), platinum doublets, e.g., cisplatin/
carboplatin plus paclitaxel, nab-paclitaxel or pemetrexed × 4 to 6 cycles
+/− bevacizumab, are routinely recommended for patients without any
targetable mutations followed by the option of single-agent pemetrexe,
docetaxel, or erlotinib. For so-called T790M-negative tumors, second-line
therapy is a chemotherapy doublet. Options for patients with T790M
mutation–negative tumors that progress on chemotherapy are limited.

EGFR Inhibition Beyond Progression

Based on the concept of “oncogene addiction” in which tumors,
dependent on oncogenes such as EGFR for their continued proliferation
and survival, experience accelerated regrowth or “flare” after stopping TKI
therapy, progressive disease on a TKI does not necessarily equate with

exhausted benefit. Accordingly, one option is to continue TKIs beyond
progression in asymptomatic patients. In a 2013 study, Yang et al. [28],
having stratified TKI-failed patients according to three types of progression
(dramatic, gradual, and local), demonstrated that the continuation of EGFR
TKI is feasible for gradual and local progression (+ local modalities such
as surgical resection, stereotactic radiotherapy, and cryotherapy);
continued sensitivity to therapy is suggested. For dramatic progression,
chemotherapy, not EGFR TKI continuation, is indicated as well as a
biopsy to rule out histologic transformation from NSCLC to small cell
lung cancer, which constitutes an additional resistance mechanism to
TKI therapy [29].
The effect of TKI continuation past true progression in EGFR + NSCLC
was also explored in the ASPIRATION “Asian Pacific Trial of Tarceva as
First-Line in EGFR Mutation” and IMPRESS “IRESSA
Mutation-Positive Multicenter Treatment Beyond Progression Study.”
In the nonrandomized ASPIRATION (Asian Pacific trial of Tarceva as
first‐line in EGFR mutation) study, patients with indolent, smallvolume asymptomatic growth, i.e., gradual progressors and oligometastatic progressors, selected at investigators' discretion, that were
continued on single-agent erlotinib beyond RECIST progression
showed an improvement in PFS by 3.1 months [30] from 11.0 to 14.1.
However, in the randomized Phase 3 IMPRESS (IRESSA Mutation‐
Positive Multicenter Treatment Beyond Progression Study), patients that
remained on gefitinib during doublet chemotherapy did not experience
improved response rates or PFS, which established doublet chemotherapy
as the standard of care after progression on EGFR TKIs [31].
Nevertheless, the overall consensus is that while dramatic progression
mandates a change in treatment strategy, EGFR TKI continuation in the
setting of oligometastatic disease is a feasible option [32] to delay the time
to progression and the need for subsequent platinum-based treatments,
eventually with the addition of local therapy.

Continuation of EGFR TKI with Brain Metastases
The incidence of brain metastases in NSCLC is 25% to 30%, and
that incidence is increased in EGFR-mutated NSCLC to 44% to
63% [33], possibly because patients live longer on TKIs and the risk
of brain metastases increases with lifespan or possibly because the
propensity to metastasize is greater in EGFR-mutated cancers. For
patients with oligometastatic progression in the brain after EGFR
TKI therapy, the consensus is to continue EGFR TKI with local
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therapies such as radiotherapy, surgery, and stereotactic ablative
radiotherapy on the suspicion that poor blood brain barrier
penetration of the TKI rather than cellular resistance [34] is to
blame; in this case, EGFR TKI continuation may serve to maintain
systemic remission. Jackman et al. [24]. demonstrated that high-dose
gefitinib penetrates the blood-brain barrier more effectively, and
likewise, pulsatile high-dose erlotinib was found to overcome
acquired resistance to standard-dose erlotinib [35].

Treatment-Free Interval (Drug Holiday)
Despite the potential for disease flare during an EGFR TKI–free
period, restoration of TKI sensitivity, which may be epigenetically
mediated, has been documented after a drug holiday. In a study of 23
patients who were rechallenged with gefitinib after a median 7-month
break, during which time they received cytotoxic anticancer therapy,
Tomizawa et al. [36] reported a partial response rate of 22% and a
disease control rate of 65%. In a retrospective study of 14 patients
[37], reintroduction of erlotinib after a median 9.5-month holiday
resulted in 36% (n = 5) partial response, 50% stable disease (n = 7)
,and 14% progressive disease (n = 2). However, these were
small-scale studies, and further investigation from larger prospective
trials is required to confirm these outcomes.
Alternative Treatment Strategies/Future Directions

Immunotherapy + TKI
Four randomized phase III trials have reported a statistically
significant improvement in response rate (RR) and overall survival
(OS) with immune checkpoint inhibitors such as nivolumab and
pembrolizumab over standard second-line docetaxel chemotherapy in
platinum-refractory NSCLC [38]. By contrast, EGFR-mutant
advanced NSCLC patients gained no overall survival (OS) benefit
from immune checkpoint inhibitors over docetaxel [39], which may
be related to the general lack of tobacco use in this population since
smoking is associated with a higher mutational burden, a biomarker
of response to immunotherapy [40].
Nonetheless, PD-L1 expression has been associated with EGRF
mutation [41], which has been reported to correlate with a higher
likelihood of response to PD-1 blockade, suggesting that immunotherapy
in EGFR-mutant NSCLC may still hold promise. However, despite
evidence of clinical activity, combinations of nivolumab plus erlotinib,
gefitinib plus durvalumab, and osimertinib plus durvalumab (anti–
PD-L1 monoclonal antibody) resulted in a relatively high incidence of
treatment-related grade 3 to 4 toxicities [42], and in fact, two trials with
the osimertinib plus durvalumab combination were halted due to an
excess of pulmonary toxicity. However, many new immunotherapy
agents are under development including the inhibitory molecules TIM-3,
LAG-3, IDO (indoleamine-pyrrole 2,3-dioxygenase), BTLA (B- and
T-lymphocyte attenuator), adenosine, and VISTA (V-domain immunoglobulin containing suppressor of T cell activation) and the stimulatory
molecules 4-1BB, OX40, CD40, and CD27. Therefore, the “jury is still
out” on the clinical feasibility of immunotherapy in this population.

Mesenchymal-Epidermal Transition (MET) Inhibition
Amplification (but probably not mutation) of MET, a receptor
tyrosine kinase, occurs in up to 20% of tumors [43] with acquired
resistance to EGFR TKIs, which suggests the potential for synergistic
benefit from combination treatment with an EGFR and MET
inhibitor [44]. MET amplification and T790M mutation are not
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mutually exclusive; both may coexist, or MET amplification may
occur on its own. Therefore, concomitant inhibition of MET and
EGFR is likely required. Several published case reports with a
TKI + crizotinib, a known MET and ALK inhibitor that has
demonstrated activity in MET-amplified patients, and other clinical
data [26] support this assumption [45,46]. In a Phase 2 study with
erlotinib + tivatinib, a selective c-MET inhibitor, in a TKI-failed
EGFR-positive population, a subgroup of patients with high MET
expression responded to the combination therapy, although the study as
a whole did not meet its endpoint [47]. In a Phase 1b/2 study
(NCT01610336), the combination of capmatinib (INC280), another
MET inhibitor, and gefitinib in 65 high-MET EGFR TKI-resistant
NSCLC patients yielded a disease control rate of 80% (overall response
rate 18%; stable disease 62%) [48]. In a Phase 1 study of tepotinib
(MSC2156119J) plus gefitinib, 18 patients were treated, and 5 had a
partial response [49]. While the combination of MET inhibitors and
EGFR TKIs seems promising, the potential for overlapping or additive
toxicities based on the mechanisms of action of these agents is an
important consideration, which requires testing in large clinical trials.

Oncolytic Virotherapy
Since nonsmoking EGFR-mutated NSCLC patients may resist
checkpoint therapy due to a low mutational load, treatments like
radiotherapy or virotherapy that induce the release of tumor antigens may
augment the activity of PD-1/L1 inhibitors. As cancer-specific lytic agents,
with or without therapeutic transgenes to augment the immune response,
locally injected replicating oncolytic viruses that liberate nonself neoantigens
for T-cell priming may elicit abscopal effects at distant metastatic sites;
however, unlike radiotherapy, which also is associated with abscopal effects
but may induce pneumonitis and scarring in the lungs, oncolytic viruses
have been genetically engineered for attenuation and nonpathogenicity in
normal cells and are, hence, in general, minimally host toxic.
The mechanism by which oncolytic viruses even in the absence of
therapeutic transgenes kill tumor cells and elicit a systemic immune
effect involves direct lysis of tumor cells and cell death via synthesis of
new viral particles with subsequent spread of tumor-associated
antigens and epitopes after the cell lysis [50]. When the virus is armed
with therapeutic immunomodulatory transgenes, which theoretically
enhance the immune response, the infected tumor cell serves as a
“factory” for protein synthesis such that the beneficial transgene is
overproduced and may spread to distant tumor sites via the circulation.
Talimogene laherparepvec (Imlygic), commonly referred to as
T-VEC, an attenuated herpes simplex virus type 1 virus armed with a
GM-CSF transgene that is approved for the treatment of melanoma [51],
has the potential to overcome tumor-induced T-cell anergy and thereby
enhance the activity of anti-CTLA and PD-1 antibodies in EGFRmutated NSCLC. Several oncolytic adenoviruses carrying different
immunomodulatory [52] transgenes and theoretically safer than herpes
virus appear poised to enter the clinic in early 2018 as potential
treatments for multiple tumor types including EGFR + NSCLC.

Epigenetic Resensitization

The term “epigenetics” refers to reversible modifications that influence
gene expression without directly changing or affecting the DNA coding
sequence [53]. Epigenetic alterations, which include DNA methylation,
microRNA regulation, and histone/nucleosome modifications, influence
multiple cellular processes such as transcription, replication, and repair
and are implicated in tumorigenesis and chemotherapy resistance
[54,55]. Epigenetic mechanisms have been proposed to explain the
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reversion to TKI sensitivity after a drug holiday. Epigenetic inhibitors
such as histone deacetylators and DNA methyltransferases, which
dynamically reprogram the epigenome, the collective name for
chromatin and DNA modification patterns, have been associated with
resensitization of several refractory tumor types including EGFR+
NSCLC to conventional therapies such as cisplatin and carboplatin. One
such agent is the experimental tumor-associated macrophage and
neutrophil-repolarizing agent RRx-001, which in Phase 2 clinical trials
has been shown to resensitize refractory TKI- and chemotherapy-failed
EGFR-positive NSCLC patients [27] to subsequently administered
platinum doublets. If successful, the potential to reverse resistance to
chemotherapy and possibly TKIs as well might significantly improve
overall survival in this last-line population.
Conclusion and discussion
While EGFR TKI inhibitors yield impressive and durable responses,
prolonged PFS, and improved quality of life when compared to
chemotherapy, inevitable resistance to them as well as to subsequent
platinum doublets is a “no man's land” of unmet medical need, as
patients at this terminal stage have exhausted all available lines of
treatment. Careful analysis of resistance mechanisms and mutation
status at the time of clinically significant disease progression may
guide the selection of subsequent treatment, if one exists; but if not,
the only options that remain to patients are local ablative therapies,
clinical trials, or hospice with poor quality of life and death at the end
of their palliative care. New strategies to prevent or reverse the
development of resistance are therefore urgently needed and include
immunotherapy, concomitant EGFR + MET inhibition, oncolytic
virotherapy, epigenetic resensitization with subsequent administra-
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tion of previously failed chemotherapies, and potentially the discovery
of currently unknown driver mutations that synergize with all of the
above especially immunotherapy.
The key advantage of immunotherapy in NSCLC is the durability of
responses. Where resistance development is a near-universal feature of
chemotherapy and targeted agents, the tumor-specific memory function
of the immune system has the potential to confer lasting remission/
regression of metastatic disease. However, as stated earlier in this review,
EGFR-mutated tumors seem not to benefit from checkpoint inhibitors
possibly due to a relatively low mutation burden despite higher levels of
PD-L1 expression, which has been shown to correlate with response.
Since it is infeasible to increase the mutational load in EGFR+ cancers,
one strategy to refocus the immune response is to selectively increase the
exposure/release of tumor neoantigens, inflammatory cytokines, and
particular damage-associated molecular patterns that can stimulate the
immune system and potentiate the efficacy of formerly inactive
checkpoint inhibitors. If successful, targeted therapies such as dual
EGFR + MET inhibition and particularly oncolytic virotherapy will
mediate release of tumor neoantigens from lysed cells along with
cytotoxics in epigenetically resensitized tumors.
On this basis, potentially optimal sequential immunotherapeutic
priming strategies to trigger the release of immunogenic antigens from
dying cancer cells in TKI- and chemotherapy-failed tumors might
include 1) pretreatment of a non–MET-amplified tumor for several
weeks with an epigenetic inhibitor before starting a cytotoxic like
cisplatin or carboplatin for four to six cycles followed by checkpoint
inhibition and 2) administration of oncolytic viruses in combination
with EGFR TKI + MET targeted therapy in MET-amplified tumors
followed by checkpoint inhibition (see Figure 3).

Figure 3. Lytic-inducing strategies in EGFR+ NSCLC are anticipated to result in the release of multiple tumor neoantigens. Tumor
neoantigens are engulfed by antigen-presenting cells and processed and presented to T cells in the context of B7 costimulatory molecules
and major histocompatibility complex. T cells express checkpoint inhibitory molecules such as PD-1 and CTLA-4, which prevent full activation.
Immune checkpoint blockade relieves immune suppression, effectively taking the brakes off the T cells and restoring their effector function to
effectively attack the tumor. Abbreviations: CTLA-4, cytotoxic T lymphocyte–associated protein 4; MCH, major histocompatibility complex;
PD1, programmed cell death protein 1; PD-L1, PD1 ligand; TCR, T-cell receptor. Adapted from Sharma P, Allison JP. Immune checkpoint
targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015;161:205-14.
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The cancer-immunity cycle proposed by Chen and Mellman
consists of seven steps [56]: 1) release of cancer antigens, 2) cancer
antigen presentation, 3) priming and activation, 4) T-cell trafficking
to tumors, 5) T-cell tumor infiltration, 6) recognition of cancer cells
by T cells, and 7) killing of cancer cells.
In this cycle, the induction of an immune response begins when
professional APCs, such as dendritic cells, engulf apoptotic or necrotic
tumor cells and present tumor-associated antigens on their surface to
their cognate T cells. A prerequisite for immune cell–mediated tumor
cell destruction is interaction of the antigen-specific T cells with
MHC-I-peptide complexes. Since NSCLC, like melanoma, kidney,
and urothelial cancers, typically (although not always) presents as
inflamed or T-cell rich, steps 1, 2, and 3 (i.e., release of cancer
antigens, cancer antigen presentation, and priming and activation)
arguably play the most important role in EGFR-mutated NSCLC.
In summary, while possibly an oversimplification of complex
oncoimmunology, the overall low mutation load in EGFR+ NSCLC
may render these tumors preferentially susceptible to lytic-inducing
strategies that amplify intratumoral T cells against undefined antigens
prior to administration of checkpoint inhibitors. Besides viruses,
targeted therapies, epigenetic inhibitors, and cytotoxic chemotherapies other potentially lytic-inducing agents may include adoptive cell
transfer therapies such as CAR-T, cytokines such as IL-2 and IL-15,
bacteria and yeast vectors, and personalized polyepitope DNA
vaccines that are selected on the basis of mutation status and MHC
binding affinity.
The opposite of no man's land is a fertile plain. It is hoped that, in the
near future, new, innovative strategies will be available to overcome
resistance mechanisms, especially immunologically based resistance
mechanisms, and thereby transform the no man's land of TKI- and
chemotherapy-failed EGFR+ NSCLC into a vast fertile plain, rich with
promising therapeutic options that result in meaningful improvements
to quality of life and survival.
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